Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,747.60
(
2.00%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
100.37
(
-7.18%
)
Bitcoin
70,542.29
(
3.99%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 182052

Saturday, 09/20/2014 5:41:36 PM

Saturday, September 20, 2014 5:41:36 PM

Post# of 257269
Re: ABT-493 + ABT-530 (from #msg-106413637)

It’s not immediately clear why the GT1 trial is accepting treatment-experienced patients only if they were null responders to IFN/RBV.

If anyone has a thesis regarding this design feature, please post!

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today